Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

25.37 -0.70 (-2.69%)
Streaming Delayed Price Updated: 10:45 AM EDT, Oct 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
The Latest Analyst Ratings for Travere Therapeutics
 
Via Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Additional Data From Travere Therapeutics' Kidney Disease Candidate Reinforce Efficacy, Supporting Ongoing Launch
 
Via Benzinga
Travere Therapeutics Announces Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy Published in The Lancet and Presented at World Congress of Nephrology 2023
FILSPARI demonstrated a statistically significant, rapid, and sustained decline of proteinuria compared to the active control 
From Travere Therapeutics, Inc.
Via GlobeNewswire
Could an FDA Approval Send This Stock Flying?
Is now the time to load up on this struggling stock? 
Via The Motley Fool
Travere Therapeutics's Return On Capital Employed Overview
 
Via Benzinga
Why Travere Therapeutics Stock Bolted Higher This Week
A high-value regulatory approval lit a fire underneath the biotech's shares this week. 
Via The Motley Fool
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
3 Up-and-Coming Growth Stocks to Buy Right Now
These companies are small now but could grow much larger over time. 
Via The Motley Fool
Travere Therapeutics Announces Late-Breaker Presentations of the Interim Analysis from the Phase 3 PROTECT Study of FILSPARI™ (Sparsentan) in IgA Nephropathy at the ISN World Congress of Nephrology and NKF Spring Clinical Meetings 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing
The high-flyers have soared to new heights and further gains could be up ahead. 
Via The Motley Fool
Travere Therapeutics's Earnings Outlook
 
Via Benzinga
What 10 Analyst Ratings Have To Say About Travere Therapeutics
 
Via Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders 44th Annual Meeting and the American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters’ Option to Purchase Additional Shares
From Travere Therapeutics, Inc.
Via GlobeNewswire
Analyst Views Multiple Opportunities For Chinook To Thrive In Emerging Renal Markets, Sees More Than 100% Upside
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
 
Via Benzinga
Travere Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Announces Proposed Public Offering of Common Stock
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023. 
Via Benzinga
Earnings Scheduled For February 23, 2023
Companies Reporting Before The Bell • ChipMOS TECHNOLOGIES (NASDAQ:IMOS) is likely to report earnings for its fourth quarter. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
 
Via Benzinga
Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
 
Via Benzinga
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
From Ligand Pharmaceuticals Incorporated
Via Business Wire
Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.